Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature

doi:10.4251/wjgo.v15.i11.2033

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1949)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series.

Item

Count

PDF

WORD

HTML

780

Figures (1-5)

135

Sum=956

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

226

Download

343

Sum=569

Publishing Process of This Article

Item

Count

Browse

100

Download

282

Sum=382

Nov 15, 2023 (publication date) through Jun 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Nov 15, 2023; 15(11): 2033-2040
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.2033

Full Size Figure Download Figure

Figure 1 The first admission was hepatobiliary enhanced magnetic resonance imaging. A: Sagittal images shows carcinoma in the middle and lower segment of the common bile duct (orange arrow); B: Diffusion-weighted imaging images shows carcinoma size of 1.1 cm (orange circle); C: Retroperitoneal enlarged lymph nodes size of 1.5 cm (orange circle).

Citation: Luo WH, Li SJ, Wang XF. Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature. World J Gastrointest Oncol 2023; 15(11): 2033-2040
URL: https://www.wjgnet.com/1948-5204/full/v15/i11/2033.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.2033